摘要
目的:观察拉米夫定与干扰素联合用药治疗慢性乙型肝炎的疗效。方法:将150例慢性乙型肝炎患者随机分为三组,各50例。联合组给予拉米夫定和重组人干扰素α-2b治疗,拉米夫定组单给予拉米夫定治疗;干扰素组单给予干扰素治疗,疗程均为1年。结果:治疗1年后,联合组HBV-DNA转阴率为86%,血清HBeAg/抗HBe转换率为48%,均优于拉米夫定组和干扰素组(P<0.05)。联合组仅出现1例YMDD变异(2%),而拉米夫定组出现8例YMDD变异(16%)。结论:拉米夫定联合干扰素治疗效果优于单独应用组,并且能减少病毒YMDD变异,防止耐药发生。
Objective： To observe the effect of Lamivudine combination Interferon in the treatment of patients with chronic hepatitis B. Methods： 150 patients with chronic hepatitis B were divided into 3 groups, each group had 50 patients. The patients in combination group received Lamivudine and Interferonα-2b therapy for one year, the patients in lamivudine group and interferon group received lamivudine and interferonα-2b therapy respectively for one year. Results： After one year, the HBVDNA loss and HBeAg/anti-HBe seroconversion in combination group were 86% and 48%, respectively. They were higher than in Lamivudine group and Interferon group （P0.05）, YMDD mutations were detected in one patients in combination group （2%）, but 8 patients in Lamivudine group （16%）. Conclusion： Lamivudine combination Interferon in the treatment of patients with chronic hepatitis B get a better effect and decrease YMDD mutation.
出处
《中国医药导报》
CAS
2010年第28期47-48,共2页
China Medical Herald
